<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335009">
  <stage>Registered</stage>
  <submitdate>13/01/2010</submitdate>
  <approvaldate>14/01/2010</approvaldate>
  <actrnumber>ACTRN12610000041055</actrnumber>
  <trial_identification>
    <studytitle>Continuous ST Segment Monitoring and Incidence of Clinical Events in Implantable Cardioverter Defibrillator (ICD) Patients</studytitle>
    <scientifictitle>A prospective, multicenter, anonymous registry to collect data in the population of patients implanted with a St Jude Medical (SJM) AnalyST/AnalyST Accel VR/DR device intended to provide ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias.</scientifictitle>
    <utrn />
    <trialacronym>AnalyST</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ventricular arrhythmias</healthcondition>
    <healthcondition>Paroxysmal Atrial Fibrillation</healthcondition>
    <healthcondition>Persistent Atrial Fibrillation</healthcondition>
    <healthcondition>Sinus Node Dysfunction</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The study is aimed at 1/ identifying the patient population selected by physicians to be implanted with a SJM ICD featuring the ST segment monitoring feature. 2/ Documenting the incidence of ST segment shifts and possible relationships with clinical events and 3/ the change in patient management related to the device diagnositic availabiltiy. 
Patients will be observed for a period of 12 months with a maximum of Four Follow up visits</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To Identify the population of patients being selected by physicians to be implanted with a SJM ICD featuring ST segment monitoring. This will be assessed through the collection of patients medical history and demographics via the Case Report Forms (CRF's).</outcome>
      <timepoint>Implant date</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Document the Incidence of ST segment shifts, symptomatic or not, in the population and their possible relationships with clinical events. This will be achieved through Device interrogation and CRF reporting</outcome>
      <timepoint>12 months post implant, data will be collected at routine visits (max four follow up visits)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To document the change in patient management related to the availability of device diagnositcs. Physicians will record changes made to medication, device programming or tests/exams ordered on the CRFs.</outcome>
      <timepoint>12months post implant, data collected during routine visits (maximum of four follow up visits)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Any patient candidate implanted with a St Jude Medical AnalyST or AnalyST Accel DR/VR device, as per current guidelines can be enrolled in the study.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patient not willing or able to understand and sign the 'data transfer authorization'</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>31/10/2009</anticipatedstartdate>
    <actualstartdate>3/11/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>31/05/2011</actualenddate>
    <samplesize>1000</samplesize>
    <actualsamplesize>1123</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate />
    <postcode>2050</postcode>
    <postcode>2076</postcode>
    <postcode>4000</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Luxembourg</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St. Jude Medical</primarysponsorname>
    <primarysponsoraddress>St. Jude Medical World Headquarters
One Lillehei Plaza
St. Paul MN 55117</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>St. Jude Medical</fundingname>
      <fundingaddress>St. Jude Medical World Headquarters
One Lillehei Plaza
St. Paul MN 55117</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to 1/ Identify the population of patients selected by physicians to be implanted with a SJM ICD featuring the ST segment monitoring feature. 2/ Document the incidence of ST segment shifts, symptomatic or not, in that population and their possible relationships with clinical events. 3/ Document the change in patient management related to availability of device diagnostics.</summary>
    <trialwebsite />
    <publication>none known</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital Human Research Ethics Committee (HREC)</ethicname>
      <ethicaddress>Research Development Office
Level 3 Building 92
Missenden Rd
Royal Prince Alfred Hospital
Camperdown NSW 2050</ethicaddress>
      <ethicapprovaldate>20/10/2009</ethicapprovaldate>
      <hrec>X09-0211</hrec>
      <ethicsubmitdate>5/08/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sydney Adventist Hospital HREC</ethicname>
      <ethicaddress>185 Fox Valley Rd
Wahroonga NSW 2076</ethicaddress>
      <ethicapprovaldate>5/08/2009</ethicapprovaldate>
      <hrec>9/09/2010</hrec>
      <ethicsubmitdate>20/07/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Mr</title>
      <name>Kurt Dubin</name>
      <address>St. Jude Medical BCC
Corporate Village
Leonardo Da Vincilaan, 11 Box F1
Zaventem BRUSSELS 1935</address>
      <phone>+322 774 6887</phone>
      <fax />
      <email>kdubin@sjm.com</email>
      <country>Belgium</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Kurt Dubin</name>
      <address>St Jude Medical BCC
Corporate Village
Leonardo Da Vincilaan, 11 Box F1
Zaventem BRUSSELS 1935</address>
      <phone>+322 774 6887</phone>
      <fax />
      <email>kdubin@sjm.com</email>
      <country>Belgium</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Jessica Andrews</name>
      <address>St Jude Medical Australia
17 Orion Rd
Lane Cove NSW 2066</address>
      <phone>+61 2 9936 1236</phone>
      <fax>+61 2 9936 1222</fax>
      <email>jandrews04@sjm.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Michael Kilborn</name>
      <address>Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050
AUSTRALIA</address>
      <phone>+61 2 9515 7885</phone>
      <fax />
      <email>mkilborn@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>